Cognition Therapeutics (CGTX) Short Interest Ratio & Short Volume → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free CGTX Stock Alerts $2.00 +0.08 (+4.17%) (As of 05/8/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Cognition Therapeutics Short Interest DataCurrent Short Volume220,300 sharesPrevious Short Volume150,200 sharesChange Vs. Previous Month+46.67%Dollar Volume Sold Short$420,773.00Short Interest Ratio / Days to Cover1.1Last Record DateApril 15, 2024Outstanding Shares40,040,000 sharesFloat Size30,150,000 sharesShort Percent of Float0.73%Today's Trading Volume32,667 sharesAverage Trading Volume182,418 sharesToday's Volume Vs. Average18% Short Selling Cognition Therapeutics ? Sign up to receive the latest short interest report for Cognition Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatCGTX Short Interest Over TimeCGTX Days to Cover Over TimeCGTX Percentage of Float Shorted Over Time Ad Crypto Swap ProfitsHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here Cognition Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/2024220,300 shares $420,773.00 +46.7%0.7%1.1 $1.91 3/31/2024150,200 shares $273,364.00 -34.2%0.5%0.7 $1.82 3/15/2024228,100 shares $415,142.00 +79.9%1.0%1.1 $1.82 2/29/2024126,800 shares $262,476.00 +26.2%0.6%0.5 $2.07 2/15/2024100,500 shares $198,990.00 -30.9%0.5%0.5 $1.98 1/31/2024145,400 shares $330,058.00 +24.0%0.7%0.8 $2.27 Get the Latest News and Ratings for CGTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cognition Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/2024117,300 shares $236,946.00 +65.0%0.5%0.6 $2.02 12/31/202371,100 shares $131,535.00 -52.9%0.3%0.4 $1.85 12/15/2023150,900 shares $307,836.00 -23.6%0.7%0.9 $2.04 11/30/2023197,500 shares $219,225.00 -17.8%0.9%1.7 $1.11 11/15/2023240,200 shares $252,210.00 -19.1%1.1%2.4 $1.05 10/31/2023296,800 shares $332,416.00 +368.9%1.3%3.1 $1.12 10/15/202363,300 shares $70,896.00 -34.3%0.3%1.6 $1.12 9/30/202396,300 shares $138,672.00 +16.3%0.4%2.3 $1.44 9/15/202382,800 shares $104,328.00 -4.5%0.4%0.7 $1.26 8/31/202386,700 shares $134,385.00 +5.0%0.4%0.7 $1.55 8/15/202382,600 shares $123,074.00 -21.1%0.4%0.5 $1.49 7/31/2023104,700 shares $173,802.00 -36.2%0.5%0.6 $1.66 7/15/2023164,100 shares $283,893.00 -33.7%0.8%1 $1.73 6/30/2023247,600 shares $453,108.00 +131.2%1.2%1.6 $1.83 6/15/2023107,100 shares $320,229.00 +75.0%0.5%1.2 $2.99 5/31/202361,200 shares $125,460.00 -4.8%0.3%0.7 $2.05 5/15/202364,300 shares $109,953.00 -8.8%0.3%0.9 $1.71 4/30/202370,500 shares $125,490.00 -15.0%0.3%1.1 $1.78 4/15/202382,900 shares $147,562.00 -35.7%0.4%1.2 $1.78 3/31/2023128,900 shares $255,222.00 +56.6%0.6%1.7 $1.98 3/15/202382,300 shares $135,795.00 -3.1%0.4%1.1 $1.65 2/28/202384,900 shares $135,840.00 +43.9%0.5%0.9 $1.60 2/15/202359,000 shares $110,330.00 +1.0%0.4%0.3 $1.87 1/31/202358,400 shares $115,048.00 -34.9%0.3%0.3 $1.97 1/15/202389,700 shares $199,134.00 -16.8%0.5%0.5 $2.22 12/30/2022107,800 shares $226,380.00 -32.9%0.7%0.6 $2.10 12/15/2022160,600 shares $420,772.00 -49.3%1.1%0.8 $2.62 11/30/2022316,500 shares $1.11 million +136.2%2.1%1.6 $3.51 11/15/2022134,000 shares $194,300.00 +116.1%0.9%1.1 $1.45 10/31/202262,000 shares $110,360.00 +98.1%0.4%0.7 $1.78 10/15/202231,300 shares $56,966.00 -40.8%0.2%0.1 $1.82 9/30/202252,900 shares $100,510.00 +8.4%0.3%0.1 $1.90 9/15/202248,800 shares $91,256.00 +15.4%0.4%0.1 $1.87 8/31/202242,300 shares $86,715.00 +10.7%0.3%0.1 $2.05Obama’s Forever Term [exposed] (Ad)America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.Start streaming it now at no cost here CGTX Short Interest - Frequently Asked Questions What is Cognition Therapeutics' current short interest? Short interest is the volume of Cognition Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 15th, traders have sold 220,300 shares of CGTX short. 0.73% of Cognition Therapeutics' shares are currently sold short. Learn More on Cognition Therapeutics' current short interest. What is a good short interest ratio for Cognition Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CGTX shares currently have a short interest ratio of 1.0. Learn More on Cognition Therapeutics's short interest ratio. What is a good short interest percentage for Cognition Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.73% of Cognition Therapeutics' floating shares are currently sold short. Is Cognition Therapeutics' short interest increasing or decreasing? Cognition Therapeutics saw a increase in short interest in April. As of April 15th, there was short interest totaling 220,300 shares, an increase of 46.7% from the previous total of 150,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Cognition Therapeutics' float size? Cognition Therapeutics currently has issued a total of 40,040,000 shares. Some of Cognition Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Cognition Therapeutics currently has a public float of 30,150,000 shares. How does Cognition Therapeutics' short interest compare to its competitors? 0.73% of Cognition Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Cognition Therapeutics: Precision BioSciences, Inc. (9.69%), Instil Bio, Inc. (0.23%), Atara Biotherapeutics, Inc. (9.51%), Elutia Inc. (0.19%), Athira Pharma, Inc. (2.94%), Turnstone Biologics Corp. (4.76%), SCYNEXIS, Inc. (2.75%), Ikena Oncology, Inc. (5.48%), Genenta Science S.p.A. (0.02%), AlloVir, Inc. (5.57%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Cognition Therapeutics stock? Short selling CGTX is an investing strategy that aims to generate trading profit from Cognition Therapeutics as its price is falling. CGTX shares are trading up $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Cognition Therapeutics? A short squeeze for Cognition Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CGTX, which in turn drives the price of the stock up even further. How often is Cognition Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CGTX, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: DTIL Short Interest TIL Short Interest ATRA Short Interest ELUT Short Interest ATHA Short Interest TSBX Short Interest SCYX Short Interest IKNA Short Interest GNTA Short Interest ALVR Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CGTX) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressObama’s Forever Term [exposed]Porter & CompanyThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders